lamotrigine has been researched along with Bilateral Headache in 30 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the pharmacokinetics (PK) of lamotrigine (LTG) when converting from twice-daily immediate-release (LTG-IR) to once-daily extended-release (LTG-XR) in subjects with epilepsy." | 9.13 | Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study). ( Ali, I; Hammer, AE; Job, S; Lemme, F; Messenheimer, JA; Oliver-Willwong, R; Tompson, DJ; Vuong, A; Zhu, L, 2008) |
| "This randomised, double-blind study compared the newer antiepileptic drugs (AEDs) gabapentin (GBP) and lamotrigine (LTG) as monotherapy in newly diagnosed epilepsy." | 9.10 | Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. ( Anhut, H; Brodie, MJ; Chadwick, DW; Garofalo, EA; Maton, S; Messmer, SL; Murray, G; Otte, A; Sauermann, W, 2002) |
| "According to case reports and observational studies, lamotrigine therapy has resulted in decreased frequency or resolution of SUNCT syndrome attacks." | 8.87 | The role of lamotrigine in the treatment of short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing syndrome. ( Karpinski, JP; Rosselli, JL, 2011) |
| "To correlate lamotrigine (LTG) serum concentrations (levels) with tolerability in patients with epilepsy." | 8.82 | Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. ( Adams, DJ; Bazil, CW; Buchsbaum, R; Du, Y; Hager, M; Hirsch, LJ; Morrell, MJ; Resor, SR; Spencer, HT; Straka, T; Weintraub, D, 2004) |
| "To provide a qualitative, systematic update and review of the pharmacology, pharmacokinetics, efficacy in mood disorders, adverse effects, and costs of lamotrigine." | 8.81 | Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002) |
| "The purpose of this case series is to characterize a recently identified association of the antiepileptic drug (AED) lamotrigine with aseptic meningitis based on cases reported to the Food and Drug Administration (FDA)'s Adverse Event Reporting System (AERS) database." | 7.78 | Lamotrigine and aseptic meningitis. ( Avigan, M; Kortepeter, C; Simms, KM, 2012) |
| "To examine the safety of lamotrigine (LTG) used in general practice to treat epilepsy." | 7.69 | Safety of long-term lamotrigine in epilepsy. ( Freemantle, SN; Mackay, FJ; Mann, RD; Pearce, GL; Wilton, LV, 1997) |
| " Headache, drowsiness, faintness, and diplopia, the common adverse events (AEs), were mild to moderate in intensity and occurred in 50-75% of patients in both groups (except for diplopia, occurring only with LTG)." | 6.68 | Lamotrigine high-dose tolerability and safety in patients with epilepsy: a double-blind, placebo-controlled, eleven-week study. ( Gay, P; Lai, AA; Madsen, J; Matsuo, F; Risner, ME; Rollins, DE; Tolman, KG, 1996) |
| "The SUNCT syndrome is characterized by a short-lasting headache in the first division of the trigeminal nerve, associated with ipsilateral autonomic symptoms." | 6.42 | Influence of lamotrigine over the SUNCT syndrome: one patient follow-up for two years. ( Kowacs, PA; Piovesan, EJ; Siow, C; Werneck, LC, 2003) |
| "Lamotrigine is a potentially effective option for patients with SWS with migraine-like headaches." | 5.40 | Lamotrigine for intractable migraine-like headaches in Sturge-Weber syndrome. ( Fukui, M; Nomura, S; Shimakawa, S; Tamai, H; Tanabe, T, 2014) |
| "Migraine is a common cause of vertigo." | 5.32 | Treatment of migraine related vertigo with lamotrigine an observational study. ( Bisdorff, AR, 2004) |
| "To compare the pharmacokinetics (PK) of lamotrigine (LTG) when converting from twice-daily immediate-release (LTG-IR) to once-daily extended-release (LTG-XR) in subjects with epilepsy." | 5.13 | Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study). ( Ali, I; Hammer, AE; Job, S; Lemme, F; Messenheimer, JA; Oliver-Willwong, R; Tompson, DJ; Vuong, A; Zhu, L, 2008) |
| "This randomised, double-blind study compared the newer antiepileptic drugs (AEDs) gabapentin (GBP) and lamotrigine (LTG) as monotherapy in newly diagnosed epilepsy." | 5.10 | Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. ( Anhut, H; Brodie, MJ; Chadwick, DW; Garofalo, EA; Maton, S; Messmer, SL; Murray, G; Otte, A; Sauermann, W, 2002) |
| "According to case reports and observational studies, lamotrigine therapy has resulted in decreased frequency or resolution of SUNCT syndrome attacks." | 4.87 | The role of lamotrigine in the treatment of short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing syndrome. ( Karpinski, JP; Rosselli, JL, 2011) |
| "To correlate lamotrigine (LTG) serum concentrations (levels) with tolerability in patients with epilepsy." | 4.82 | Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. ( Adams, DJ; Bazil, CW; Buchsbaum, R; Du, Y; Hager, M; Hirsch, LJ; Morrell, MJ; Resor, SR; Spencer, HT; Straka, T; Weintraub, D, 2004) |
| "To provide a qualitative, systematic update and review of the pharmacology, pharmacokinetics, efficacy in mood disorders, adverse effects, and costs of lamotrigine." | 4.81 | Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002) |
| "The purpose of this case series is to characterize a recently identified association of the antiepileptic drug (AED) lamotrigine with aseptic meningitis based on cases reported to the Food and Drug Administration (FDA)'s Adverse Event Reporting System (AERS) database." | 3.78 | Lamotrigine and aseptic meningitis. ( Avigan, M; Kortepeter, C; Simms, KM, 2012) |
| "To examine the safety of lamotrigine (LTG) used in general practice to treat epilepsy." | 3.69 | Safety of long-term lamotrigine in epilepsy. ( Freemantle, SN; Mackay, FJ; Mann, RD; Pearce, GL; Wilton, LV, 1997) |
| "Nummular headache is characterized by continuous or intermittent head pain, which remains circumscribed in a round or oval area of the scalp, typically one to six centimeters in diameter." | 3.01 | Epicranial headaches part 2: Nummular headache and epicrania fugax. ( Cuadrado, ML, 2023) |
| "Lamotrigine was well tolerated in this study." | 2.73 | Lamotrigine monotherapy for newly diagnosed typical absence seizures in children. ( Frank, LM; Hammer, AE; Holmes, GL; Kerls, S; Messenheimer, J; Philbrook, B; Sheth, RD; Vuong, A; Wooten, JD, 2008) |
| " The adverse effect (AE) profile of this combination needs clarification." | 2.69 | Adding lamotrigine to valproate: incidence of rash and other adverse effects. Postmarketing Antiepileptic Drug Survey (PADS) Group. ( Faught, E; French, J; Harden, C; Jacobson, M; Montouris, G; Morris, G; Rosenfeld, W, 1999) |
| " Headache, drowsiness, faintness, and diplopia, the common adverse events (AEs), were mild to moderate in intensity and occurred in 50-75% of patients in both groups (except for diplopia, occurring only with LTG)." | 2.68 | Lamotrigine high-dose tolerability and safety in patients with epilepsy: a double-blind, placebo-controlled, eleven-week study. ( Gay, P; Lai, AA; Madsen, J; Matsuo, F; Risner, ME; Rollins, DE; Tolman, KG, 1996) |
| "Rash was the most commonly reported AE, occurring in 7." | 2.52 | Safety of lamotrigine in paediatrics: a systematic review. ( Choonara, I; Egunsola, O; Sammons, HM, 2015) |
| "Neuropathic cranial pain, i." | 2.42 | Neuropathic cranial pain. ( Annovazzi, PO; Colombo, B; Comi, G, 2003) |
| "The SUNCT syndrome is characterized by a short-lasting headache in the first division of the trigeminal nerve, associated with ipsilateral autonomic symptoms." | 2.42 | Influence of lamotrigine over the SUNCT syndrome: one patient follow-up for two years. ( Kowacs, PA; Piovesan, EJ; Siow, C; Werneck, LC, 2003) |
| "Lamotrigine is a potentially effective option for patients with SWS with migraine-like headaches." | 1.40 | Lamotrigine for intractable migraine-like headaches in Sturge-Weber syndrome. ( Fukui, M; Nomura, S; Shimakawa, S; Tamai, H; Tanabe, T, 2014) |
| "Individuals treated with combined valproate-lamotrigine rarely present late adverse effects (unrelated to introduction and titration)." | 1.38 | Late adverse effects of the coadministration of valproate and lamotrigine. ( Moreira, B; Thome-Souza, S; Valente, KD, 2012) |
| "When lamotrigine was restarted 2 weeks later she developed similar but more severe symptoms which resolved on stopping lamotrigine." | 1.35 | Anticonvulsant hypersensitivity syndrome presenting as aseptic meningitis. ( Bazaz, R; Lily, O; Maniyar, F; Rooney, C, 2009) |
| "Migraine is a common cause of vertigo." | 1.32 | Treatment of migraine related vertigo with lamotrigine an observational study. ( Bisdorff, AR, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (16.67) | 18.2507 |
| 2000's | 13 (43.33) | 29.6817 |
| 2010's | 10 (33.33) | 24.3611 |
| 2020's | 2 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cuadrado, ML | 1 |
| Criscuolo, A | 1 |
| Strumia, S | 1 |
| Di Concetto, G | 1 |
| Corso, RM | 1 |
| Weng, HY | 1 |
| Cohen, AS | 1 |
| Schankin, C | 1 |
| Goadsby, PJ | 1 |
| Yalın, OÖ | 1 |
| Uludüz, D | 1 |
| Özge, A | 1 |
| Ozudogru, S | 1 |
| Loucao, S | 1 |
| Rauf, A | 1 |
| Cortez, M | 1 |
| Lambru, G | 1 |
| Matharu, MS | 1 |
| Nomura, S | 1 |
| Shimakawa, S | 1 |
| Fukui, M | 1 |
| Tanabe, T | 1 |
| Tamai, H | 1 |
| Pulido Fontes, L | 1 |
| Mayor Gómez, S | 1 |
| Egunsola, O | 1 |
| Choonara, I | 1 |
| Sammons, HM | 1 |
| Holmes, GL | 1 |
| Frank, LM | 1 |
| Sheth, RD | 1 |
| Philbrook, B | 1 |
| Wooten, JD | 1 |
| Vuong, A | 2 |
| Kerls, S | 1 |
| Hammer, AE | 2 |
| Messenheimer, J | 1 |
| Maniyar, F | 1 |
| Rooney, C | 1 |
| Lily, O | 1 |
| Bazaz, R | 1 |
| Rosselli, JL | 1 |
| Karpinski, JP | 1 |
| Simms, KM | 1 |
| Kortepeter, C | 1 |
| Avigan, M | 1 |
| Thome-Souza, S | 1 |
| Moreira, B | 1 |
| Valente, KD | 1 |
| Brodie, MJ | 1 |
| Chadwick, DW | 1 |
| Anhut, H | 1 |
| Otte, A | 1 |
| Messmer, SL | 1 |
| Maton, S | 1 |
| Sauermann, W | 1 |
| Murray, G | 1 |
| Garofalo, EA | 1 |
| Colombo, B | 1 |
| Annovazzi, PO | 1 |
| Comi, G | 1 |
| Piovesan, EJ | 1 |
| Siow, C | 1 |
| Kowacs, PA | 1 |
| Werneck, LC | 1 |
| Hirsch, LJ | 1 |
| Weintraub, D | 1 |
| Du, Y | 1 |
| Buchsbaum, R | 1 |
| Spencer, HT | 1 |
| Hager, M | 1 |
| Straka, T | 1 |
| Bazil, CW | 1 |
| Adams, DJ | 1 |
| Resor, SR | 1 |
| Morrell, MJ | 1 |
| Frediani, F | 1 |
| Bisdorff, AR | 1 |
| Sajatovic, M | 1 |
| Gyulai, L | 1 |
| Calabrese, JR | 1 |
| Thompson, TR | 1 |
| Wilson, BG | 1 |
| White, R | 1 |
| Evoniuk, G | 1 |
| Tompson, DJ | 1 |
| Ali, I | 1 |
| Oliver-Willwong, R | 1 |
| Job, S | 1 |
| Zhu, L | 1 |
| Lemme, F | 1 |
| Messenheimer, JA | 1 |
| Matsuo, F | 2 |
| Gay, P | 1 |
| Madsen, J | 1 |
| Tolman, KG | 1 |
| Rollins, DE | 1 |
| Risner, ME | 1 |
| Lai, AA | 1 |
| Mackay, FJ | 1 |
| Wilton, LV | 1 |
| Pearce, GL | 1 |
| Freemantle, SN | 1 |
| Mann, RD | 1 |
| Faught, E | 1 |
| Morris, G | 1 |
| Jacobson, M | 1 |
| French, J | 1 |
| Harden, C | 1 |
| Montouris, G | 1 |
| Rosenfeld, W | 1 |
| D'Andrea, G | 1 |
| Granella, F | 1 |
| Cadaldini, M | 1 |
| Leone, M | 1 |
| Rigamonti, A | 1 |
| Usai, S | 1 |
| Damico, D | 1 |
| Grazzi, L | 1 |
| Bussone, G | 1 |
| Tilignac, C | 1 |
| Dordain, G | 1 |
| Hurley, SC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Lamotrigine in Subjects With Absence Seizures[NCT00144872] | Phase 1 | 54 participants (Actual) | Interventional | 2004-11-01 | Completed | ||
| A Multicentre, Double-blind, Randomized, Phase IV Clinical Trial Comparing the Safety, Tolerability and Efficacy of Levetiracetam Versus Lamotrigine and Carbamazepine in the Oral Antiepileptic Therapy of Newly Diagnosed Elderly Patients With Focal Epileps[NCT00438451] | Phase 4 | 361 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Pilot Study of Prophylactic Management of Lamotrigine for Bipolar Disorder in Pregnant Women[NCT03774641] | 20 participants (Anticipated) | Observational | 2018-12-03 | Recruiting | |||
| An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine When Switching Patients With Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa[NCT00264615] | Phase 3 | 45 participants | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00438451)
Timeframe: 58 weeks
| Intervention | proportion of participants (Mean) |
|---|---|
| Levetiracetam | 0.61 |
| Carbamazepine | 0.46 |
| Lamotrigine | 0.56 |
Percentage of patients experiencing no seizures until week 58 (Visit 6) and did not discontinue the study until week 58. (NCT00438451)
Timeframe: week 58
| Intervention | percentage of participants (Number) |
|---|---|
| Levetiracetam | 43 |
| Carbamazepine | 33 |
| Lamotrigine | 38 |
Percentage of patients experiencing no seizures until week 30 (Visit 4) and did not discontinue the study until week 30. (NCT00438451)
Timeframe: Week 30
| Intervention | percentage of participants (Number) |
|---|---|
| Levetiracetam | 48 |
| Carbamazepine | 39 |
| Lamotrigine | 49 |
(NCT00438451)
Timeframe: 52 weeks
| Intervention | proportion of seizure-free days (Number) |
|---|---|
| Levetiracetam | 0.99 |
| Carbamazepine | 0.99 |
| Lamotrigine | 0.99 |
EPITrack-Score shows the performance of attention and executive functions. Higher values indicate a better performance. The results of EPITrack Score ranges between 7 and 45. (NCT00438451)
Timeframe: week 58
| Intervention | units on a scale (Mean) |
|---|---|
| Levetiracetam | 26.0 |
| Carbamazepine | 26.0 |
| Lamotrigine | 25.4 |
"Seizure frequency was assessed by investigators in the CRF at the Visits V3, V4, V5 and V6.~The absolute seizure frequency during the maintenance phase was defined as the sum of those entries." (NCT00438451)
Timeframe: over 52 weeks
| Intervention | number of seizures (Number) |
|---|---|
| Levetiracetam | 168 |
| Carbamazepine | 131 |
| Lamotrigine | 130 |
(NCT00438451)
Timeframe: over the whole duration of 58 weeks
| Intervention | days (Median) |
|---|---|
| Levetiracetam | NA |
| Carbamazepine | NA |
| Lamotrigine | NA |
number of days between randomization and premature discontinuation of the study (NCT00438451)
Timeframe: 58 weeks
| Intervention | days (Median) |
|---|---|
| Levetiracetam | NA |
| Carbamazepine | 265 |
| Lamotrigine | NA |
"The PNS is a 15-item scale. Each item can be scored from 1 to 9. There are a total score (includes all items, range:15 to 135) and two subscores: The cognitive toxicity subscore (10 items: Energy Level, Memory, Interest, Concentration, Forgetfulness, Sleepliness, Moodiness, Alertness, Attention Span, Motivation, range:10 to 90) and the somatomoto subscore (5 items: Vision, Walking, Coordination, Tremor, Speech, range:5-45). The score is calculated by taking the mean of all non-missing values times the number of items.~Lower values indicate better quality of life." (NCT00438451)
Timeframe: at week 58
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Cognitive toxicity subscore | Somatomotor subscore | Total Score | |
| Carbamazepine | 27.3 | 11.4 | 38.7 |
| Lamotrigine | 23.7 | 10.8 | 34.5 |
| Levetiracetam | 22.2 | 10.5 | 32.7 |
The QOLIE-31 is a 31 item score that measures the quality of life in epilepsy (each item with a range of 0 to 100). There are 7 sub-scores seizure worry (items 11,21,22,23,25), overall quality of life (items 1,14), emotional well-being (items 3,4,5,7,9), energy/fatigue (items 2,6,8,10), cognitive functioning (items 12,15,16,17,18,26), medication effects (items 24,29,30) and social functioning (13,19,20,27,28). These scores were combined to a total score by Total score = seizure worry*0.08 + overall quality of life*0.14 + emotional well-being*0.15 + energy/fatigue*0.12 + cognitive functioning*0.27 + medication effects*0.03 + social functioning*0.21 For all scores, higher values indicate better quality of life. Each score has a possible range from 0 to 100. (NCT00438451)
Timeframe: 58 weeks, final visit
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Seizure worry | Overall quality of life | Emotional well-being | Energy/fatigue | Cognitive functioning | Medication effects | Social functioning | Total Score | Health Scale | |
| Carbamazepine | 75.4 | 65.0 | 69.8 | 54.5 | 68.9 | 70.6 | 76.3 | 68.9 | 65.7 |
| Lamotrigine | 75.0 | 67.1 | 67.4 | 59.8 | 68.0 | 72.6 | 76.7 | 69.1 | 67.5 |
| Levetiracetam | 85.1 | 67.2 | 72.0 | 60.8 | 75.1 | 77.6 | 81.1 | 73.9 | 69.5 |
"Evaluation of current testing at V6:~≥29 score points: Inconspicuous; 26 to 28 score points: Borderline;~≤25 score points: Impaired" (NCT00438451)
Timeframe: 58 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| Without pathological findings | Borderline | Impaired | |
| Carbamazepine | 34 | 17 | 33 |
| Lamotrigine | 31 | 15 | 39 |
| Levetiracetam | 38 | 10 | 36 |
"Evaluation of Changes~Changes in the EpiTrack® Score were categorized as follows:~≥5 score points: Improved;~-3 to 4 score points: Unchanged;~≤-4 score points: Worsened" (NCT00438451)
Timeframe: week 58
| Intervention | participants (Number) | ||
|---|---|---|---|
| Improved | Unchanged | Worsened | |
| Carbamazepine | 16 | 56 | 8 |
| Lamotrigine | 15 | 53 | 13 |
| Levetiracetam | 15 | 61 | 6 |
10 reviews available for lamotrigine and Bilateral Headache
| Article | Year |
|---|---|
Epicranial headaches part 2: Nummular headache and epicrania fugax.
Topics: Chronic Pain; Gabapentin; Headache; Headache Disorders; Humans; Lamotrigine | 2023 |
SUNCT and SUNA: medical and surgical treatments.
Topics: Analgesics; Headache; Humans; Lamotrigine; Lidocaine; SUNCT Syndrome; Triazines; Trigeminal Autonomi | 2013 |
Safety of lamotrigine in paediatrics: a systematic review.
Topics: Abdominal Pain; Anticonvulsants; Child; Dizziness; Drug Therapy, Combination; Exanthema; Headache; H | 2015 |
The role of lamotrigine in the treatment of short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing syndrome.
Topics: Anticonvulsants; Calcium Channel Blockers; Headache; Humans; Lamotrigine; Stevens-Johnson Syndrome; | 2011 |
Neuropathic cranial pain.
Topics: Acetates; Amines; Analgesics; Analgesics, Non-Narcotic; Anticonvulsants; Antidepressive Agents, Tric | 2003 |
Influence of lamotrigine over the SUNCT syndrome: one patient follow-up for two years.
Topics: Analgesics; Headache; Humans; Lamotrigine; Male; Middle Aged; Syndrome; Triazines | 2003 |
Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Drug Eruptions; Drug Interactions; Drug Therapy, | 2004 |
Anticonvulsant drugs in primary headaches prophylaxis.
Topics: Amines; Anticonvulsants; Carbamazepine; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Fruct | 2004 |
Lamotrigine.
Topics: Adolescent; Adult; Animals; Anticonvulsants; Child; Clinical Trials as Topic; Diplopia; Dizziness; D | 1999 |
Lamotrigine update and its use in mood disorders.
Topics: Acetates; Aggression; Amines; Antidepressive Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; | 2002 |
7 trials available for lamotrigine and Bilateral Headache
| Article | Year |
|---|---|
Phenotypic and treatment outcome data on SUNCT and SUNA, including a randomised placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Anticonvulsants; Cross-Over Studies; Female; | 2018 |
Lamotrigine monotherapy for newly diagnosed typical absence seizures in children.
Topics: Anticonvulsants; Child; Child, Preschool; Electroencephalography; Epilepsy, Absence; Female; Headach | 2008 |
Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Asthenia; Clinical Protocols; Cyclohexan | 2002 |
Maintenance treatment outcomes in older patients with bipolar I disorder.
Topics: Adult; Antipsychotic Agents; Back Pain; Bipolar Disorder; Dose-Response Relationship, Drug; Double-B | 2005 |
Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study).
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Area Under Curve; | 2008 |
Lamotrigine high-dose tolerability and safety in patients with epilepsy: a double-blind, placebo-controlled, eleven-week study.
Topics: Adolescent; Adult; Anticonvulsants; Diplopia; Dose-Response Relationship, Drug; Double-Blind Method; | 1996 |
Adding lamotrigine to valproate: incidence of rash and other adverse effects. Postmarketing Antiepileptic Drug Survey (PADS) Group.
Topics: Adolescent; Adult; Child; Dizziness; Drug Eruptions; Drug Hypersensitivity; Drug Therapy, Combinatio | 1999 |
13 other studies available for lamotrigine and Bilateral Headache
| Article | Year |
|---|---|
Acupuncture and lamotrigine for acute short unilateral neuralgiform headache attacks with conjunctival injection and tearing syndrome: a case report.
Topics: Acupuncture Therapy; Aged, 80 and over; Calcium Channel Blockers; Conjunctiva; Headache; Humans; Inj | 2021 |
Peripheral nerve blocks for the treatment of short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT) during pregnancy.
Topics: Adult; Anticonvulsants; Diagnosis, Differential; Female; Headache; Humans; Lamotrigine; Nerve Block; | 2018 |
Post-stroke short-lasting unilateral neuralgiform headache attacks with autonomic symptoms (SUNA): response to lamotrigine and sphenopalatine ganglion block.
Topics: Anticonvulsants; Combined Modality Therapy; Headache; Humans; Lamotrigine; Male; Middle Aged; Spheno | 2019 |
Lamotrigine for intractable migraine-like headaches in Sturge-Weber syndrome.
Topics: Adolescent; Analgesics, Non-Narcotic; Cognition; Headache; Humans; Lamotrigine; Male; Neuropsycholog | 2014 |
SUNCT (Short-lasting unilateral neuralgiform headache attack with conjunctival injection and tearing) associated with pituitary lesion.
Topics: Excitatory Amino Acid Antagonists; Headache; Humans; Lamotrigine; Magnetic Resonance Imaging; Male; | 2015 |
Anticonvulsant hypersensitivity syndrome presenting as aseptic meningitis.
Topics: Anti-Bacterial Agents; Anticonvulsants; Drug Administration Schedule; Drug-Related Side Effects and | 2009 |
Lamotrigine and aseptic meningitis.
Topics: Adolescent; Adult; Aged; Algorithms; Animals; Anticonvulsants; Antidepressive Agents; Bipolar Disord | 2012 |
Late adverse effects of the coadministration of valproate and lamotrigine.
Topics: Adolescent; Anticonvulsants; Ataxia; Child; Drug Therapy, Combination; Epilepsy; Female; Headache; H | 2012 |
Treatment of migraine related vertigo with lamotrigine an observational study.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Female; Headache; Humans; Lamotrigine; Male; Middle Aged | 2004 |
Safety of long-term lamotrigine in epilepsy.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Anticonvulsants; Chil | 1997 |
Possible usefulness of lamotrigine in the treatment of SUNCT syndrome.
Topics: Aged; Calcium Channel Blockers; Conjunctival Diseases; Dose-Response Relationship, Drug; Female; Hea | 1999 |
Two new SUNCT cases responsive to lamotrigine.
Topics: Aged; Conjunctival Diseases; Female; Headache; Humans; Lacrimal Apparatus Diseases; Lamotrigine; Mal | 2000 |
[SUNCT syndrome sensitive to lamotrigine].
Topics: Analgesics; Cerebrospinal Fluid Rhinorrhea; Conjunctival Diseases; Female; Functional Laterality; He | 2001 |